CEO Ramon Laguarta said the Doritos maker hasn’t seen a “direct impact” from GLP-1 medications despite a higher level of awareness among consumers toward health and wellness.
CEO Ramon Laguarta said the Doritos maker hasn’t seen a “direct impact” from GLP-1 medications despite a higher level of awareness among consumers toward health and wellness.
